Industry News
Insights into pharmaceutical industry trends and breakthrough technologies
All News
43 articles in total
Ten Key Peptide Modifications: Chemistry and Implications for Custom Synthesis
Peptide modification chemistry changes the functional groups attached to a peptide or protein scaffold. For R&D and CDMO teams, the practical question is not only which modification appears on a sequence; it is where the modification sits, whether it survives the route, how it changes purification, and which analytical methods can distinguish intended material from close impurities.
Reported 2026 ASCO ADC Themes: Design Control for New Formats
The reported 2026 ASCO education-session themes frame next-generation antibody-drug conjugate work around engineering variables: target engagement, payload pairing, payload novelty, DAR design, and dose strategy. For CHEMOS readers, the useful point is not that any format has been proven superior. It is that each new ADC format moves more risk into linker-payload synthesis, conjugation control, analytical methods, formulation assumptions, and evidence discipline.
Cancer Cell Review Links ADC Performance to Tumor Ecosystem Biology
The practical message from the Cancer Cell review is that an antibody-drug conjugate cannot be evaluated by target presence alone. An ADC must bind an antigen, reach the relevant intracellular trafficking route, release a payload in the intended compartment, and be assessed in the tumor and patient context described by the review. That makes precision ADC development a combined biology, chemistry, and analytics problem.
On-Resin Disulfide Formation in Peptide SPPS
On-resin disulfide formation builds a cysteine-cysteine bond while the peptide remains attached to a solid-phase synthesis resin. For CHEMOS readers, the practical question is whether this placement can simplify workup and control intramolecular cyclization without creating new impurity risks. The process variables are linked: oxidant choice, protecting groups, resin swelling, solvent salts, reaction time, and TFA scavenger composition can all affect the final crude peptide profile.
GalNAc-siRNA ADME: Uptake, Metabolism, and DDI Lessons
For oligonucleotides, the familiar small-molecule ADME checklist is useful as a list of questions, not as a mechanistic shortcut. These molecules are large, highly charged nucleic acid polymers that rely on non-oral delivery, uptake pathways, and nuclease-driven metabolism. For CHEMOS readers, the chemistry translation is direct: GalNAc building blocks, linker behavior, backbone modification, nuclease stability, and LC-MS method design all affect what downstream ADME data can mean.
Glycan-Directed ADC Conjugation: Donor Design and DAR Control
OBI Pharma's WO2026117757 describes a method for building site-specific antibody-drug conjugates through the conserved N297 glycan region of an antibody. The workflow trims native N-glycans to a core GlcNAc acceptor, installs functionalized sugar donors, and then couples linker-payload units by bioorthogonal chemistry. CHEMOS readers should care because the disclosure frames DAR as a glycan-donor design variable, not only as an outcome of stochastic lysine or cysteine conjugation.